As of November 16, 2026, InMed Pharmaceuticals Inc. is a publicly traded company (Nasdaq: INM). The largest holder reporting an active stake on Schedule 13D is Vivo Opportunity Fund Holdings, L.P., at 21.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include ADAR1 Capital (17.2%), Sabby Management, LLC (9.9%), Squadron Master Fund LP (9.8%) (Schedule 13D, June 10, 2026).
Is this your company?
About to sign with, pay or invest in InMed Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is InMed Pharmaceuticals Inc. a real, registered company?
- Mentari Therapeutics, Inc. files with the SEC under CIK 1728328 (its SEC filings).
- Its shares are listed under the ticker INM on Nasdaq (also MTRI) (SEC company record).
- Incorporated in A1, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under InMed Pharmaceuticals Inc. in our court records and SEC 8-K records (as of 2026-11-16).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-03-06).
- Leadership changes: the latest reported is Gregory Divis, President and Chief Executive Officer (Form 8-K filed 2026-11-10). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Deep Track Capital (filed 2026-11-13).
Who are InMed Pharmaceuticals Inc.'s owners and officers?
InMed Pharmaceuticals Inc.: industry Pharmaceutical Preparations (Schedule 13G, 2026-11-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2022-12-06)
- : Executive Officer (Form D, 2022-12-06)
- : Executive Officer (Form D, 2022-12-06)
- : Executive Officer (Form D, 2022-12-06)
- : Director (Form D, 2022-12-06)
- : Director (Form D, 2022-12-06)
- : Director (Form D, 2022-12-06)
- : Director (Form D, 2022-12-06)
- : Director (Form D, 2022-12-06)
- : Executive Officer (Form D, 2022-12-06)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-13 | Deep Track Capital, LP | 5.64% |
| Schedule 13G, 2026-11-13 | Commodore Capital LP | 5.6% |
| Schedule 13D, 2026-11-12 | Fairmount Funds Management LLC | 19.99% |
| Schedule 13G/A, 2026-10-07 | Adar1 Capital Management, LLC | 17.2% |
| Schedule 13G, 2026-08-14 | Ikarian Capital, LLC | 4.2% |
| Schedule 13D, 2026-06-10 | Vivo Opportunity Fund Holdings, L.P. | 21.7% |
| Schedule 13G, 2026-06-05 | Adar1 Capital Management, LLC | 24.1% |
| Schedule 13G, 2026-05-27 | Squadron Master Fund LP | 9.8% |
| Schedule 13G, 2026-01-20 | Sabby Management, LLC | 9.9% |
Questions about who owns InMed Pharmaceuticals Inc.
Who owns InMed Pharmaceuticals Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of InMed Pharmaceuticals Inc.: Vivo Opportunity Fund Holdings, L.P. (21.7%, Schedule 13D, filed 2026-06-10), Fairmount Funds Management LLC (19.99%, Schedule 13D, filed 2026-11-12), Adar1 Capital Management, LLC (17.2%, Schedule 13G/A, filed 2026-10-07), Sabby Management, LLC (9.9%, Schedule 13G, filed 2026-01-20) and Squadron Master Fund LP (9.8%, Schedule 13G, filed 2026-05-27); 2 more are listed above.
Who are the largest shareholders of InMed Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of InMed Pharmaceuticals Inc. on this page are Vivo Opportunity Fund Holdings, L.P. (21.7%), Fairmount Funds Management LLC (19.99%) and Adar1 Capital Management, LLC (17.2%).
When did Vivo Opportunity Fund Holdings, L.P. buy into InMed Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Vivo Opportunity Fund Holdings, L.P. on this page is the Schedule 13D, filed 2026-06-10, reporting 21.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on InMed Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on InMed Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InMed Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-10 | Gregory Divis | President and Chief Executive Officer | appointed | |
| Form 8-K, 2026-11-10 | Brett Hagen | appointed |
Which insiders own InMed Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 10,555,507 shares, held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 3, 2026-11-12).
- , a 10% owner: 10,555,507 shares, held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 3, 2026-11-12).
- Fairmount Funds Management LLC, a 10% owner: 10,555,507 shares, held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 3, 2026-11-12).
- Fairmount Healthcare Fund II L.P., a 10% owner: 10,555,507 shares, held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 3, 2026-11-12).
- Vivo Opportunity Cayman Fund, L.P., a 10% owner: 818,076 shares (14.9% of shares outstanding), held indirectly through By Vivo Opportunity Cayman Fund, L.P. and 1 other, on a joint filing (Form 4, 2026-07-16).
Shares outstanding: 5,493,735 as of 2026-10-30, from the company's latest SEC cover page.
How much has InMed Pharmaceuticals Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2022-12-06 | $6M | $6M |
Latest IPO step: InMed Pharmaceuticals Inc. amended its IPO registration (S-1/A, 2025-08-01).
IPO filings: S-1/A, 2025-08-01, S-1, 2025-07-09, S-1/A, 2024-12-30, S-1, 2024-12-23; ticker INM on Nasdaq Capital Market.
Acquisitions reported on Form 8-K, Item 2.01: acquired Mentari (2026-11-10).
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-03-06).
Keep reading
More on InMed Pharmaceuticals Inc. and the records around it.
InMed Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Acquisition Nov 2026
- Leadership changes Nov 2026
- Layoff notices Mar 2026
Companies that share a holder
- Fairmount Funds Management LLC also filed stake reports on 14 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/mentari-therapeutics